Cancer And Mitosis Research Paper

In normal cells, hundreds of genes intricately control the process of cell division. Normal growth requires a balance between the activity of those genes that promote cell proliferation and those that suppress it. It also relies on the activities of genes that signal when damaged cells should undergo apoptosis.

Cells become cancerous after mutations accumulate in the various genes that control cell proliferation. According to research findings from the Cancer Genome Project, most cancer cells possess 60 or more mutations. The challenge for medical researchers is to identify which of these mutations are responsible for particular kinds of cancer. This process is akin to searching for the proverbial needle in a haystack, because many of the mutations present in these cells have little to nothing to do with cancer growth.

Different kinds of cancers have different mutational signatures. However, scientific comparison of multiple tumor types has revealed that certain genes are mutated in cancer cells more often than others. For instance, growth-promoting genes, such as the gene for the signaling protein Ras, are among those most commonly mutated in cancer cells, becoming super-active and producing cells that are too strongly stimulated by growth receptors. Some chemotherapy drugs work to counteract these mutations by blocking the action of growth-signaling proteins. The breast cancer drug Herceptin, for example, blocks overactive receptor tyrosine kinases (RTKs), and the drug Gleevec blocks a mutant signaling kinase associated with chronic myelogenous leukemia.

Other cancer-related mutations inactivate the genes that suppress cell proliferation or those that signal the need for apoptosis. These genes, known as tumor suppressor genes, normally function like brakes on proliferation, and both copies within a cell must be mutated in order for uncontrolled division to occur. For example, many cancer cells carry two mutant copies of the gene that codes for p53, a multifunctional protein that normally senses DNA damage and acts as a transcription factor for checkpoint control genes.

By drilling down to the atomic level of how specific proteins interact during cell division, or mitosis, a team of scientists has found a unique new target for attacking cancer.

PROVIDENCE, R.I. [Brown University] — Structural biologists show in a new study that an apparently key step in the process of cell division depends on a unique interaction among specific proteins, including one that is strongly linked to cancer. Their hope now is that the detailed new characterization of the interaction will make it a target for exploring a new cancer therapy.

Cell division, or mitosis, is a staple of high school biology classwork, but scientists are still making new discoveries about its intricate workings. Now, researchers have discovered that as copied chromosomes begin to exit mitosis and pull away from their sisters to form a new cell, a stage called anaphase, a protein called Ki-67 brings a protein called PP1 to the chromosomes.

Mitosis is essential to life, but it is also a process that occurs to a runaway degree in cancer. And that made Ki-67 of particular interest to the authors of the new study, which appears in the journal eLife, because Ki-67 is highly expressed throughout the various stages of mitosis, said lead author Senthil Kumar, assistant professor (research) of molecular pharmacology, physiology and biotechnology at Brown University.

“Ki-67 is a protein that is widely used as a prognostic marker in cancer biology,” Kumar said. “People use this as a marker to study how far cancer has progressed.”

Along with fellow Brown faculty members Wolfgang Peti and Rebecca Page and colleagues from other institutions, Kumar therefore wanted to understand exactly how Ki-67 interacts with PP1 in anaphase to bring it to the chromosomes. It turns out that Ki-67 binds to PP1 very tightly and — they also show this to exacting degrees in the new study — that another protein called RepoMan acts just like Ki-67.

Understanding how the proteins and PP1 interact during anaphase, the researchers hoped, could reveal a way to perhaps reduce or slow down mitosis in tumors.

It was particularly important to achieve a precise characterization of Ki-67 and RepoMan’s interaction with PP1, Page said, because PP1 interacts with hundreds of proteins in the body, which regulate many key processes that they wouldn’t want to hinder. Instead, they wanted to see if there was something specific in mitosis with these two regulator proteins that they could pinpoint.

“PP1 has this interaction with 200 different regulators, but a number of those regulators use a couple of [binding] sites over and over again,” said Page, professor of molecular, cellular biology and biochemistry. “You obviously can’t develop an inhibitor for those two sites, because then you’d disrupt PP1 function in a whole array of biological processes. But the really neat thing that Senthil discovered is that this whole interaction is completely unique to these two regulators.”

Kumar and Page led the effort by using nuclear magnetic resonance and x-ray crystallography that resolved the proteins and their interactions down to the scale of individual atoms — 1.3 tenths of billionths of a meter. What he and the team found was that RepoMan and Ki-67 were binding with PP1 in an unusual way, forming a “hairpin” shape on the surface of PP1 at specific locations. A bioinformatics database search later confirmed that the binding was unique.

Moreover, they identified a novel binding region which is unique only to RepoMan and Ki-67. This novel region could be a potential target for cancer therapy, Kumar said.

Crucial to the research was that in the anaphase of mitosis the binding is even more specific than just either protein linking up with just any form of PP1. Instead they showed that in anaphase, RepoMan and Ki-67 link to a particular form of PP1 called gamma. The proteins’ selectivity for PP1-gamma, they found, depended on just one amino acid on the PP1 protein at position 20.

The team, including co-authors at Brunel University in London and the University of Leuven in Belgium, confirmed this in living cells in imaging studies. They also confirmed that preference for Ki-67 and RepoMan to the gamma form of PP1 happens in the live cells during mitosis. In addition, they showed that substituting the single amino acid at position 20 stopped the function.

The exact role that PP1-gamma or the two regulator proteins may play in cancer is not yet known, Page said, but now they know exactly how they interact and that the interaction is unique. That pushes the door wide open to develop a way to hinder it so they can see what the consequences are for cancer when they do.

“Now we have an approach for trying to dissect what’s really happening because we can target this interface in particular,” Page said.

In addition to Kumar, Page and Peti at Brown, the study’s other authors are Ezgi Gokhan and Paola Vagnarelli at Brunel and Sofie De Munter and Matthieu Bollen at Leuven.

The National Institutes of Health (U.S.), the Fund for Scientific Research (Belgium) and the Biotechnology and Biological Science Research Council (U.K.) funded the research.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *